IP Library Granted Patent US 9,598,469
Granted Patent B2
US 9,598,469 · App. 14/141,396 · Granted Mar 21, 2017

HIV-1 south african subtype C env proteins

Inventors: Jan Zur Megede (San Francisco, CA); Susan Barnett (San Francisco, CA); Ying Lian (Albany, CA); Susan Engelbrecht (Tygerberg, ZA); Estrelita Janse Van Rensberg (Tygerberg, ZA); Thomas J. Scriba (Oxford, GB)
Assignees: Novartis Vaccines and Diagnostics, Inc.; University of Stellenbosch
C07K14/005A61K39/21C12N15/86A61K39/00A61K39/12A61K2039/53C12N2720/00034C12N2740/16043C12N2740/16052C12N2740/16122C12N2740/16222C12N2740/16322C12N2799/027C12N2800/108C12N2830/42C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,469
App. No.
14/141,396
Granted
Mar 21, 2017
Kind
B2
Abstract

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

Claims (16)

1. A polypeptide comprising a heterologous leader peptide and an amino acid sequence having at least 98% sequence identity to an Env protein of SEQ ID NO: 3.

2. A composition comprising a polypeptide comprising an amino acid sequence having at least 98% sequence identity to an Env protein of SEQ ID NO: 3 and an adjuvant.

3. The composition of claim 2 , wherein the composition is formulated for administration intramuscularly, intramucosally, intranasally, subcutaneously, intradermally, transdermally, intravaginally, intrarectally, orally or intravenously.

4. The polypeptide of claim 1 , wherein the Env protein is selected from the group consisting of gp120, o-gp140, gp120ΔV2, o-gp140ΔV2, gp120ΔV1V2 and o-gp140ΔV1V2.

5. The polypeptide of claim 1 , wherein the polypeptide comprises mammalian cell glycosylation.

6. The polypeptide of claim 5 , wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.

7. The polypeptide of claim 5 , wherein the cell is a CHO cell.

8. A polypeptide comprising an amino acid sequence having at least 98% sequence identity to an Env protein of SEQ ID NO: 3, wherein the polypeptide does not comprise human cell glycosylation.

9. The polypeptide of claim 8 , wherein the Env protein is selected from the group consisting of gp120, o-gp140, gp120ΔV2, o-gp140ΔV2, gp120ΔV1V2 and o-gp140ΔV1V2.

10. The polypeptide of claim 8 , wherein the cell is selected from the group consisting of BHK, VERO, COS-7, and CHO cells.

11. The polypeptide of claim 8 , wherein the cell is a CHO cell.

12. A composition comprising the polypeptide of claim 8 and an adjuvant.

13. The composition of claim 2 , wherein the Env protein is selected from the group consisting of gp120, o-gp140, gp120ΔV2, o-gp140ΔV2, gp120ΔV1V2 and o-gp140ΔV1V2.

14. The composition of claim 2 , wherein the polypeptide comprises mammalian cell glycosylation.

15. The polypeptide of claim 5 , wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.

16. The polypeptide of claim 5 , wherein the cell is a CHO cell.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Jul 22, 2015
From: NOVARTIS BIOTECH PARTNERSHIP, INC.; CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 036157/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ENGELBRECHT, SUSAN; VAN RENSBERG, ESTRELITA JANSE; SCRIBA, THOMAS JENS
To: UNIVERSITY OF STELLENBOSCH
Reel/Frame 035632/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ZUR MEGEDE, JAN; BARNETT, SUSAN W.; LIAN, YING
To: CHIRON CORPORATION
Reel/Frame 035632/0837 →
Continuity (7)
Continuation 13399977 · Feb 17, 2012
Continuation 11724050 · Mar 13, 2007
Division 10190435 · Jul 5, 2002
Provisional Application 60303192 · Jul 5, 2001
Provisional Application 60316860 · Aug 31, 2001
Provisional Application 60349871 · Jan 16, 2002
Related Publication 20140220060A1 · Aug 7, 2014